Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer

NCT04828395 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

65

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

BIOLOGICAL: Camrelizumab
DRUG: Fluzoparib
DRUG: Cisplatin，Pemetrexed
DRUG: Cisplatin，Etoposide
DRUG: Carboplatin, Albumin Paclitaxel
RADIATION: Radiotherapy

Sponsor

Tianjin Medical University Cancer Institute and Hospital